Sunnybrook Research Institute

MOLLI Surgical Awarded INOVAIT Research Funding Through Pilot Fund Awards

Retrieved on: 
Wednesday, June 21, 2023
IGT, Sunnybrook Research Institute, Medicine, Strategic Innovation Fund, Next, Gold, Time (magazine), Invention, Local government in Canada, Artificial intelligence, FDA, TIME, Medical device, Pharmaceutical industry, SRI

Funding for this project was provided in part by INOVAIT through the Government of Canada's Strategic Innovation Fund.

Key Points: 
  • Funding for this project was provided in part by INOVAIT through the Government of Canada's Strategic Innovation Fund.
  • "Through this round of the INOVAIT Pilot Fund, we are allocating $1.6 million to several high value projects — including MOLLI Surgical's — to advance Canada's IGT sector."
  • In 2023, MOLLI Surgical launched two new products, MOLLI 2® and MOLLI re.markable™, paving the way for the next generation of healthcare.
  • With the support of the Pilot Fund, MOLLI is poised to deliver on that mission.

Development in Alzheimer's disease diagnosis in Canada: New tests help patients and caregivers make timely decisions

Retrieved on: 
Thursday, June 8, 2023
Exercise, CT, Radioactive decay, Diet, Bureau of Oceans and International Environmental and Scientific Affairs, Health, Sunnybrook Research Institute, Health care, Roche, Sleep, Pathology, Alzheimer Society of Canada, Ageing, PET, Brain, Research, Risk, Biomarker, Dementia, Amyloid, Incidence, MRI, Science, Protein, Tau, Patient, Laboratory, Physician, Blood, ISCB Senior Scientist Award, Amnesia, CSF, Diagnosis, Cerebrospinal fluid, Fluid mechanics, Health Canada, Empowerment, Automation, Disease, Medical imaging, Nursing, Alzheimer's disease, QC

These play a role in normal brain function; abnormal levels of these proteins are directly related to Alzheimer's disease.

Key Points: 
  • These play a role in normal brain function; abnormal levels of these proteins are directly related to Alzheimer's disease.
  • In AD, measuring changes in biomarkers can help medical teams understand how quickly a patient's condition may be advancing, and potentially, predict how it may develop in the future.
  • Earlier and more accurate diagnoses allow patients to be aware of their AD progress and to adopt appropriate lifestyle changes while preparing for the future.
  • Since cognitive decline may be misinterpreted as a normal characteristic of aging, early diagnosis through biomarkers would help facilitate the identification of patients facing cognitive decline as a result of AD."

Synaptive Medical Inc. Awarded Inaugural INOVAIT Focus Fund Investments to Fund MRI Project

Retrieved on: 
Monday, March 6, 2023
Strategic Innovation Fund, Diagnosis, Artificial intelligence, Sunnybrook Research Institute, Neoplasm, Local government in Canada, MRI, Dalhousie University, Research and development, Investment, Stroke, Neurology, AI, ENT, Pharmaceutical industry, Medical imaging, Research

The Focus Fund investments will support commercialization-focused research and development projects for Canadian technology companies at the intersection of advancing imaging, minimally invasive surgery, and artificial intelligence.

Key Points: 
  • The Focus Fund investments will support commercialization-focused research and development projects for Canadian technology companies at the intersection of advancing imaging, minimally invasive surgery, and artificial intelligence.
  • “We are very excited to be participating in such a forward looking and timely initiative,” said Cameron Piron, Co-founder, and President at Synaptive Medical.
  • “It is an honour to have been selected for investment from INOVAIT,” said Alex Panther, Director of Research and Development at Synaptive Medical.
  • Funding for this project was provided in part by INOVAIT through the Government of Canada's Strategic Innovation Fund.

Government of Canada announces the recipients of support from INOVAIT's Focus Fund

Retrieved on: 
Wednesday, January 18, 2023
IGT, University, Sunnybrook, Ageing, Face, Sunnybrook Research Institute, Parliamentary system, Government, Machine learning, The Honourable, Partnership, Growth, Therapy, Patient, Intelligence, Municipal government in Canada, Emergency, Research, Stroke, Pharmaceutical industry, Animal, Medical device, Health, AI, Science

That is why the Government of Canada continues to invest in the health care industry to ensure Canada remains a world leader in medical innovations.

Key Points: 
  • That is why the Government of Canada continues to invest in the health care industry to ensure Canada remains a world leader in medical innovations.
  • Today, Adam van Koeverden, Parliamentary Secretary to the Minister of Health and to the Minister of Sport, on behalf of the Honourable François-Philippe Champagne, Minister of Innovation, Science and Industry, announced the 14 recipients of support from INOVAIT's Focus Fund.
  • Thanks to the INOVAIT Focus Fund, we are seeing more jobs, growth and game-changing solutions that will benefit Canada."
  • Today's recipients of Focus Fund support will help position Canada and its industries as world leaders in this sector.

Major investment in top talent in ALS research

Retrieved on: 
Thursday, November 24, 2022
Municipal government in Canada, Doctor of Philosophy, Western University, Organization, ALS Society of Canada, Society, Fellow, University, Health Canada, Knowledge, Partnership, Brain, Education, Friends, Research, Fondation Botnar, Disease, Sunnybrook Research Institute, ALS, Ill, University of Ottawa Heart Institute, Amyotrophic lateral sclerosis, Medical device, Medicine, Dentistry, Hospital

Toronto, ON, Nov. 24, 2022 (GLOBE NEWSWIRE) -- The ALS Society of Canada (ALS Canada) and Brain Canada are powering innovative discoveries and treatments for amyotrophic lateral sclerosis (ALS) through exciting new research funding.

Key Points: 
  • Toronto, ON, Nov. 24, 2022 (GLOBE NEWSWIRE) -- The ALS Society of Canada (ALS Canada) and Brain Canada are powering innovative discoveries and treatments for amyotrophic lateral sclerosis (ALS) through exciting new research funding.
  • Being able to move the needle on ALS research means supporting the brightest minds that will be a key component of labs focused on improving the lives of people and families living with ALS, says Dr. David Taylor, Vice President Research and Strategic Partnerships, ALS Canada.
  • Through the ALS Canada Research Program, we fund peer-reviewed research grants, foster collaboration and build capacity within Canadas ALS research and clinical community, and invest in new areas of research positioned to have high impact.
  • As the only national dedicated source of funding for ALS research across Canada, the ALS Canada Research Program aims to accelerate research impact by providing funding for the most promising ALS projects focused on translating scientific discoveries into treatments for ALS.

KA Imaging Announces New Strategic Funding Fueling Innovation

Retrieved on: 
Wednesday, November 2, 2022
Health, Security, Medical Devices, Technology, Software, General Health, Radiology, Algorithm, Virtus Investment Partners, CEO, Acquisition, Indigenous self-government in Canada, Partnership, Intelligence, NDT, Sunnybrook Research Institute, IQT, Technology, Investment, Reveal, Patient, Artificial intelligence, The Emergency Room, Emergency department, Medical imaging

In-Q-Tel, Inc. and INOVAIT are now part of the strong list of partners working with KA Imaging.

Key Points: 
  • In-Q-Tel, Inc. and INOVAIT are now part of the strong list of partners working with KA Imaging.
  • KA Imaging, in partnership with Sunnybrook Research Institute, will obtain X-ray images from patients, and use it to develop new material separation imaging algorithms for real-time image-guided therapy applications.
  • Funding for this project was provided in part by INOVAIT through the Government of Canada's Strategic Innovation Fund.
  • KA Imaging has also signed a strategic investment and technology development agreement with In-Q-Tel, the not-for-profit strategic investor that accelerates the development and delivery of cutting-edge technologies to the U.S. intelligence and national security community and its allies.

QT Imaging, the University of Illinois, and the Sunnybrook Research Institute Receive $3.1 Million National Cancer Institute Grant for Breast Cancer Treatment Monitoring

Retrieved on: 
Thursday, October 13, 2022
Physician, Federal Food, Drug, and Cosmetic Act, Woman, QT, Computer, Research, NIH, Sunnybrook Research Institute, Technology, University, MM, National Cancer Institute, Department, TUM Department of Electrical and Computer Engineering, National, Breast cancer, Radiation, University of Illinois Urbana-Champaign, Electricity, FDA, UIUC, Algorithm, Medical imaging

NOVATO, Calif., Oct. 13, 2022 /PRNewswire/ -- QT Imaging, Inc., a medical imaging company focused on the development and clinical adoption of novel products for breast cancer imaging, today announced the award of a five-year National Cancer Institute grant to study the progress of neo-adjuvant therapy for women with breast cancer using the QTscan. The grant will use QT Imaging's Breast Scanning System enhanced with reflection back-scatter algorithms developed by the University of Illinois to assess tumor response to treatment in days rather than weeks or months. The study is a collaboration of Dr. James Wiskin, Principal Scientist at QT Imaging, Prof. Michael Oelze in the Department of Electrical and Computer Engineering at the University of Illinois Urbana-Champaign (UIUC), and Dr. Gregory Czarnota from the Radiation Oncology Department of the Sunnybrook Research Institute in Toronto, Canada. 

Key Points: 
  • Only some women benefit from early-stage chemotherapy for breast cancer.
  • QT Imaging is a privately held company engaged in the research, development, and commercialization of an innovative automated imaging system producing high-resolution transmission ultrasound images.
  • The company has received FDA 510(K) clearance for its QT Imaging Breast Scanner.
  • The QT Imaging Breast Scanner is indicated for use as an ultrasonic imaging system to provide reflection-mode and transmission-mode images of a patient's breast.

Qu Biologics to Launch Phase 2B Clinical Trial to Assess Reduction of Postoperative Immune Suppression and Disease Progression in Patients with Late-Stage Colorectal Cancer

Retrieved on: 
Monday, September 26, 2022
BC Cancer Agency, VP, Center, Ethics, Sunnybrook Health Sciences Centre, Conditional sentence, Site, Hope, Colorectal cancer, GI, Innovation, SSIS, SSI, Achievement, Biomolecular Object Network Databank, Immunotherapy, Survival, Ottawa Hospital Research Institute, Patient, Infection, Lung cancer, NK, Cancer, Forward-looking statement, Gastroenterology, Health Canada, Liver disease, Ulcerative colitis, Immunosenescence, CEO, Liver, Clinical trial, Sunnybrook Research Institute, Biotechnology, GLOBE, HIV disease progression rates, Immune system, Medical imaging, Vaccine, Pharmaceutical industry

Major surgery results in immune paralysis in the days following surgery that can contribute to cancer growth and metastases, leading to poor outcomes for cancer patients undergoing surgical treatment.

Key Points: 
  • Major surgery results in immune paralysis in the days following surgery that can contribute to cancer growth and metastases, leading to poor outcomes for cancer patients undergoing surgical treatment.
  • Dr. Hal Gunn, CEO of Qu Biologics, stated, A majority of patients diagnosed with cancer undergo surgery in the hope of cure.
  • This exciting study is designed to test whether we can prevent that postoperative immune suppression resulting in improved outcomes and survival.
  • Qu Biologics has completed four Phase 2 studies in lung cancer, Crohns disease, and ulcerative colitis.

Annovis Bio to Participate on Alzheimer's Association International Conference Panel

Retrieved on: 
Monday, August 1, 2022
AAIC, Neurodegeneration, Translational neuroscience, Gian Maria Annovi, Reno 1868 FC, University, Company, Security (finance), LinkedIn, Sunnybrook Research Institute, Brain, Doctor of Science, Neuroimaging, Panel, U.S. Securities and Exchange Commission, Human, Interest, Biomarker, National Institute of General Medical Sciences, Memory, Cognition, Pathology, Case Western Reserve University, Twitter, CEO, Parkinson's disease, Risk, Conference, Central nervous system, AD, Annual report, Toxicology, Toxicity, Axonal transport, Forward-looking statement, NYSE, PD, National Institute, Pharmacology, Principal, Inflammation, MD, Patient, Pharmacokinetics, Systems biology, AM, Pharmaceutical industry, Medical imaging, Medicine, Psychiatry, Alzheimer's disease

BERWYN, Pa., Aug. 1, 2022 /PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company addressing neurodegenerative diseases, announced that Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis, will be participating on the Systems Biology of Alzheimer's Disease Panel at the Alzheimer's Association International Conference (AAIC).

Key Points: 
  • The panel will focus on the need and underpinning rationale for advancing novel therapeutic approaches for Alzheimer's disease.
  • The panel is scheduled to take place on August 4th, 2022, at 8-9:15 AM Pacific Time / 11 AM - 12:15 PM Eastern Time.
  • Interested parties may access a live panel discussion through the AAIC 2022 conference site and archived webcast of the presentation on the Company's investor relations website at: www.annovisbio.com .
  • For more information on Annovis Bio, please visit the Company's website www.annovisbio.com and follow us on LinkedIn and Twitter .

Amylyx Pharmaceuticals Announces Partnership Agreement with Sunnybrook Research Institute to Identify Novel Drug Candidates for Neurodegenerative Diseases

Retrieved on: 
Monday, July 18, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Research, SEC, University, Investigational New Drug, Patient, LinkedIn, ISCB Senior Scientist Award, Neurodegeneration, U.S. Securities and Exchange Commission, Communication, ALS, Sunnybrook Research Institute, Therapy, Private Securities Litigation Reform Act, Twitter, Protein, Vance DeGeneres, Principal investigator, Brain, Medication, Survival, Failure rate, IND, Motor neuron, NASDAQ, Cell death, EMEA, COVID-19, Entrepreneurship, Sunnybrook Health Sciences Centre, Toxicity, Bak, Spinal cord, Amyotrophic lateral sclerosis, Pharmaceutical industry, SRI, Bax

ALS is a relentlessly progressive and fatal neurodegenerative disorder caused by motor neuron death in the brain and spinal cord.

Key Points: 
  • ALS is a relentlessly progressive and fatal neurodegenerative disorder caused by motor neuron death in the brain and spinal cord.
  • We are thrilled to work with Amylyx to have a laser-focus on identifying potentially novel therapeutic candidates for ALS and other neurodegenerative diseases.
  • At the end of this two-year agreement, Amylyx will have the right to license and develop any drug candidates that are identified by the research being conducted by SRI.
  • Sunnybrook Research Institute (SRI) is the research arm of Sunnybrook Health Sciences Centre, an internationally recognized academic health sciences centre fully affiliated with the University of Toronto.